



- *Professor*
  - *Director, Adult Cystic Fibrosis Program*
  - *Rebecca Runyon Bryan Chair in Cystic Fibrosis*
  - *Department of Medicine*
  - *Division of Pulmonary, Critical Care & Sleep Medicine*
- 

**Conditions Treated:**

- *Bronchiectasis Overview*
- *Cystic Fibrosis (CF)*

**Research Areas:**

- *Cystic Fibrosis (CF)*
- *Infectious Diseases*
- *Inflammation*

**Programs & Services:**

- *Bronchiectasis Treatment Program*
- *NTM Center of Excellence*
- *Division of Pulmonary, Critical Care and Sleep Medicine (Adult)*
- *Adult Cystic Fibrosis Clinic*
- *Department of Medicine*
- *Cystic Fibrosis Program (Adult)*

**Research Interests**

Pulmonary inflammation, host response to *Pseudomonas aeruginosa* and nontuberculous mycobacteria.

**Board Certification**

1992, 2002: American Board of Internal Medicine  
1997, 2007: ABIM- Critical Care  
1996, 2005: ABIM- Pulmonary

**Education**

1981 - 1985 Washington State University (Pullman, WA), BS, Biochemistry, Summa Cum Laude  
1985 - 1989 University of Washington School of Medicine (Seattle, WA), MD

**Residency**

1989 - 1992 University of Washington (Seattle, WA), Internal Medicine

**Fellowship**

1993 - 1997 University of Colorado Denver, Pulmonary and Critical Care Medicine

**Teaching or Professional Positions**

2008-Present: Rebecca Runyon Bryan Chair in Cystic Fibrosis  
2005-Present: Director, University of Colorado Adult Cystic Fibrosis Program

**Affiliations with the University of Colorado Denver**

2011-present: Professor, Division of Pulmonary Science and Critical Care Medicine, University of Colorado Denver

### **Awards & Recognition**

2014: Best Doctors in America, Best Doctors, Inc.

### **Publications**

Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of *Pseudomonas aeruginosa* biofilm development: human F-actin and DNA as targets for therapy. *J Med Microbiol.* 2009 Apr;58(Pt 4):492-502.

Saavedra MT, Hughes GJ, Sanders LA, Carr M, Rodman DM, Coldren CD, Geraci MW, Sagel SD, Accurso FJ, West J, Nick JA. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. *Am J Respir Crit Care Med.* 2008 Nov 1;178(9):929-38.

Smoak K, Madenspacher J, Jeyaseelan S, Williams B, Dixon D, Poch KR, Nick JA, Worthen GS, Fessler MB. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. *J Immunol.* 2008 Mar 1;180(5):3305-12.

Saavedra MT, Patterson AD, West J, Randell SH, Riches DW, Malcolm KC, Cool CD, Nick JA, Dinarello CA. Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways. *Am J Respir Cell Mol Biol.* 2008 Jun;38(6):679-88.

Silva E, Arcaroli J, He Q, Svetkauskaite D, Coldren C, Nick JA, Poch K, Park JS, Banerjee A, Abraham E. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. *Intensive Care Med.* 2007 Oct;33(10):1829-39.

### **Doctor's Contact Information**

Office: 877.225.5654

Fax: 303.270.2257

### **Locations**

National Jewish Health Main Campus  
1400 Jackson St.

Denver, CO 80206

Saint Joseph Hospital  
1835 Franklin Street

Denver, CO 80218